Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares soared over 14% ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at ...

Eli Lilly jumped by 14.30 percent on Thursday to end at $839.96 each as investor sentiment was buoyed by announcements that its new GLP-1 weight loss pill, orforglipron, demonstrated positive results ...

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety ...

The stock's fall snapped a three-day winning streak.